Novogen's NV-128 Targets the mTOR Pathway to Block Differentiation and Induce Cell Death in Ovarian Cancer Stem Cells
20 avr. 2009 08h00 HE
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - April 20, 2009) - Data presented
yesterday at the Annual Meeting of the American Association for Cancer
Research in Denver has demonstrated that...
Marshall Edwards, Inc., to Undertake Analysis of Ovature Trial
14 avr. 2009 08h20 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - April 14, 2009) - Marshall Edwards,
Inc., (NASDAQ: MSHL) today announced that it will be undertaking an
un-blinded analysis of the data from its...
Board Changes at Novogen Limited Announced
23 mars 2009 10h46 HE
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 23, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) is pleased to announce the appointment of Mr. William
D. Rueckert to its Board of...
Biotech Analyst Joins Board of Directors of Marshall Edwards, Inc.
19 mars 2009 13h07 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 19, 2009) - Marshall Edwards, Inc.
(NASDAQ: MSHL) is pleased to announce the appointment of Leah Cann to the
Board of Directors of the...
Novogen's NV-128 Targets the mTOR Pathway to Induce Cell Death in Epithelial Ovarian Cancer Stem Cells
18 mars 2009 11h16 HE
|
Novogen, Limited
NEW CANAAN, CT--(Marketwire - March 18, 2009) - NV-128, a Novogen, Ltd. (ASX: NRT) (NASDAQ: NVGN) compound, induced cell death in ovarian cancer stem cells in a
dose-dependent manner. The study...
Triphendiol Safety Data Clears the Way for Compound to Be Studied Further in the Treatment of Pancreatic Cancer
18 mars 2009 09h22 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - March 18, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL). An
abstract titled "Pre-clinical Toxicology of Triphendiol (NV-196)" will be
presented at the Annual Meeting of...
Yale Researchers Present Results of Phase II Phenoxodiol Clinical Trial in Prostate Cancer Patients at ASCO 2009 Genitourinary Cancers Symposium
24 févr. 2009 08h00 HE
|
Marshall Edwards, Inc.
ORLANDO, FL--(Marketwire - February 24, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) --
Preliminary results from a Phase II clinical trial of oral phenoxodiol in
patients with prostate cancer to be...
Novogen to Focus on Oncology Program
13 févr. 2009 09h27 HE
|
Novogen Limited
SYDNEY, AUSTRALIA--(Marketwire - February 13, 2009) - Australian pharmaceutical R&D company,
Novogen Limited (ASX: NRT) (NASDAQ: NVGN) today advised it would focus its
activities on its oncology...
Marshall Edwards, Inc. to Present at the 27th Annual JPMorgan Healthcare Conference
14 janv. 2009 08h59 HE
|
Marshall Edwards, Inc.
WASHINGTON, DC--(Marketwire - January 14, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) will
present at the 27th Annual JPMorgan Healthcare Conference in San Francisco
on Thursday January 15, 2008 at...
Marshall Edwards, Inc. Granted IND for Triphendiol
07 janv. 2009 08h10 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - January 7, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) today
announced that it has been granted an Investigative New Drug (IND) approval
by the United States Food and...